7.78 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||7.78 x 900|
|Ask||7.79 x 1300|
|Day's Range||7.45 - 7.80|
|52 Week Range||5.52 - 11.30|
|Beta (3Y Monthly)||0.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.50|
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Quotient (QTNT) delivered earnings and revenue surprises of 7.69% and -2.75%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
First European hypercare launch site initiated following CE mark approvalInitial Serological Disease Screening microarray submitted for CE marking U.S. field trial activities.
Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JERSEY, Channel Islands, July 22, 2019 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first.
The latest earnings release Quotient Limited's (NASDAQ:QTNT) announced in May 2019 indicated that losses became...
Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the Board of Directors’ decision to amend Chief Executive Officer (CEO) Franz Walt’s employment agreement to be auto-renewable. “Under Mr. Walt’s leadership, Quotient has consistently met its milestones and is now positioned for a successful future. The contract amendment allows us to secure the continuity in leadership which is essential for sustainable success,” said Heino von Prondzynski, the Company’s Chairman of the Board.
Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the submission of its completed dossier for the CE Mark (Conformité Européenne) of its initial Serological Disease Screening (SDS) Microarray for use with its CE marked MosaiQTM diagnostic platform. “The timely submission of our initial SDS microarray is yet another major step for the Company, advancing our efforts to demonstrate the effectiveness of MosaiQ in the transfusion diagnostics marketplace. The next steps include the submission of the initial SDS microarray for FDA approval by November this year,” said Franz Walt, the Company’s Chief Executive Officer.
"The end to the U.S. Government shutdown, reports of progress on China-U.S. trade talks, and the Federal Reserve’s confirmation that it did not plan further interest rate hikes in 2019 allayed investor fears and drove U.S. markets substantially higher in the first quarter of the year. Global markets followed suit pretty much across the board […]
JERSEY, Channel Islands, June 05, 2019 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer,.
Anyone researching Quotient Limited (NASDAQ:QTNT) might want to consider the historical volatility of the share price...
The Eysins, Jersey-based company said it had a loss of 41 cents per share. The blood test developer posted revenue of $8.3 million in the period. For the year, the company reported that its loss widened ...
CE mark received on the initial Immunohematology microarray in April 20192018 manufacturing site certification and MosaiQ™ device CE mark combine with the recent approval to.
JERSEY, Channel Islands, May 21, 2019 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer,.
Quotient Limited (QTNT), an established, commercial-stage diagnostics company (the Company), today announced the U.S. Food and Drug Administration (FDA) has approved the commercialization of seven additional blood bank reagents for extended antigen typing, completing the Company’s core product offering to the US market. In March 2018, seven Quotient reagents were also approved by the FDA, including two market firsts. “Quotient has more than tripled our FDA approved product offering since coming directly to market in the U.S. We continue to be motivated to bring high-quality, customer-friendly products to the U.S. market, and are sincerely grateful to our customers for their ongoing support,” said Bill Brady, VP US Commercial at Quotient.
JERSEY, Channel Islands, May 14, 2019 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth.
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 15 S&P 500 stocks […]
Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced receipt of the CE Mark (Conformité Européenne) for its initial Immunohematology (IH) Microarray for use with its CE Marked MosaiQTM diagnostic platform. Following the successful conclusion of its first EU field trial in July 2018 and the subsequent submission of the technical dossier for CE Mark approval in late September 2018, on April 30, 2019, the Company was informed that it had received CE Mark clearance for its initial IH Microarray for use in transfusion diagnostics.
Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), today reported positive EU field trial performance data for its initial MosaiQ™ Serological Disease Screening (SDS) Microarray. Field trial results for the initial MosaiQ SDS Microarray used for the detection of CMV and Syphilis achieved the required clinical performance. The field trial data was obtained by donor center testing laboratories using microarrays manufactured in Quotient’s ISO audited manufacturing facility and run on the CE marked MosaiQ instrument.